Patent · US Active

Treatment of ascites

US9655945B2 · kind B2 · utility

4Cited by
1References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 30, 2016
Grant dateMay 23, 2017
Priority date—
Expiry dateJun 30, 2036

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P1/16
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.